MacroGenics, Inc. (MGNX)
NASDAQ$2.22
Market Cap
$139.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
707 of 924
Rank in Industry
403 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MGNX Insider Trading Activity
MGNX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $800,231 | 2 | 100 |
Related Transactions
| Smith Beth Ann | VP, Controller & Treasurer | 0 | $0 | 1 | $1,083 | $-1,083 |
| Peters Jeffrey Stuart | Senior VP and General Counsel | 0 | $0 | 1 | $799,148 | $-799,148 |
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug …
Insider Activity of MacroGenics, Inc.
Over the last 12 months, insiders at MacroGenics, Inc. have bought $0 and sold $800,231 worth of MacroGenics, Inc. stock.
On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $12.92M and sold $1.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $669,585 was made by BIOTECH TARGET N V (10 percent owner) on 2023‑10‑02.
List of Insider Buy and Sell Transactions, MacroGenics, Inc.
| 2025-02-15 | Sale | Smith Beth Ann | VP, Controller & Treasurer | 423 0.0007% | $2.56 | $1,083 | +0.54% | |
| 2024-04-04 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 51,395 0.0725% | $15.55 | $799,148 | -79.89% | |
| 2024-03-06 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 19,625 0.0317% | $21.50 | $421,938 | -82.98% | |
| 2024-03-04 | Sale | Karrels James | SVP, CFO and Secretary | 30,000 0.0481% | $20.50 | $615,000 | -82.17% | |
| 2024-03-04 | Sale | Risser Eric Blasius | Chief Operating Officer | 41,159 0.0636% | $19.76 | $813,501 | -82.17% | |
| 2024-03-04 | Sale | Spitznagel Thomas | Sr VP, Technical Ops | 10,000 0.0156% | $20.00 | $200,000 | -82.17% | |
| 2024-02-26 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 16,124 0.0266% | $17.22 | $277,655 | -77.57% | |
| 2024-02-07 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 3,334 0.0069% | $18.00 | $60,012 | -76.65% | |
| 2024-02-05 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 76,251 0.1454% | $16.50 | $1.26M | -75.52% | |
| 2024-02-01 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0231% | $15.00 | $199,740 | -73.02% | |
| 2024-01-19 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0216% | $12.00 | $159,792 | -64.71% | |
| 2023-12-20 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 18,880 0.031% | $10.08 | $190,310 | -54.68% | |
| 2023-10-02 | BIOTECH TARGET N V | 10 percent owner | 150,000 0.2413% | $4.46 | $669,585 | +42.19% | ||
| 2023-09-07 | BIOTECH TARGET N V | 10 percent owner | 200,000 0.324% | $5.26 | $1.05M | +20.64% | ||
| 2023-08-30 | HURWITZ EDWARD | director | 15,000 0.0244% | $4.91 | $73,650 | +30.00% | ||
| 2023-03-10 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 5,372 0.0099% | $6.03 | $32,393 | +19.64% | |
| 2023-02-14 | BIOTECH TARGET N V | 10 percent owner | 500,000 0.7819% | $5.07 | $2.53M | +15.84% | ||
| 2023-01-19 | BIOTECH TARGET N V | director | 150,000 0.245% | $5.30 | $794,925 | +10.10% | ||
| 2022-12-27 | BIOTECH TARGET N V | director | 200,000 0.3249% | $5.61 | $1.12M | +1.25% | ||
| 2022-12-23 | BIOTECH TARGET N V | director | 200,000 0.3225% | $5.88 | $1.18M | -4.55% |
Total: 117
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.15%
| BIOTECH TARGET N V | 10 percent owner | 9929963 15.8213% | $22.04M | 19 | 0 | <0.0001% |
| Karrels James | SVP, CFO and Secretary | 171452 0.2732% | $380,623.44 | 1 | 3 | +137.87% |
| Costa Paulo F | director | 59435 0.0947% | $131,945.70 | 1 | 0 | +41.83% |
| HURWITZ EDWARD | director | 33074 0.0527% | $73,424.28 | 1 | 1 | +30% |
| Galbraith Kenneth | director | 0 0% | $0 | 1 | 1 | <0.0001% |
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$16,245,616 | 40 | 123.58% | $122.63M | |
$909,129 | 37 | 42.19% | $127.55M | |
$35,190,048 | 32 | 37.32% | $150.49M |
MGNX Institutional Investors: Active Positions
| Increased Positions | 63 | +44.68% | 5M | +8.36% |
| Decreased Positions | 57 | -40.43% | 5M | -8.28% |
| New Positions | 23 | New | 1M | New |
| Sold Out Positions | 21 | Sold Out | 873,156 | Sold Out |
| Total Postitions | 147 | +4.26% | 56M | +0.09% |
MGNX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bellevue Group Ag | $24,428.00 | 15.76% | 9.93M | 0 | 0% | 2024-12-31 |
| Armistice Capital, Llc | $15,439.00 | 9.96% | 6.28M | +18,000 | +0.29% | 2024-12-31 |
| Blackrock, Inc. | $12,441.00 | 8.03% | 5.06M | -348,297 | -6.44% | 2024-12-31 |
| Vanguard Group Inc | $10,619.00 | 6.85% | 4.32M | -40,859 | -0.94% | 2024-12-31 |
| Wasatch Advisors Lp | $8,582.00 | 5.54% | 3.49M | +952,691 | +37.57% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $7,812.00 | 5.04% | 3.18M | +164,938 | +5.48% | 2024-12-31 |
| Millennium Management Llc | $7,047.00 | 4.55% | 2.86M | -671,179 | -18.98% | 2024-12-31 |
| State Street Corp | $3,598.00 | 2.32% | 1.46M | +35,142 | +2.46% | 2024-12-31 |
| Geode Capital Management, Llc | $3,526.00 | 2.28% | 1.43M | +26,341 | +1.87% | 2024-12-31 |
| Acadian Asset Management Llc | $3,176.00 | 2.05% | 1.29M | +199,098 | +18.23% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.